Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer

por Crumley, A B C, McMillan, D C, McKernan, M, McDonald, A C, Stuart, R C
Publicado 2006

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

por Hamilton, C A, Cheung, M K, Osann, K, Chen, L, Teng, N N, Longacre, T A, Powell, M A, Hendrickson, M R, Kapp, D S, Chan, J K
Publicado 2006

A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer

por Sharma, R, Rivory, L, Beale, P, Ong, S, Horvath, L, Clarke, S J
Publicado 2006

Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials

por Chau, I, Cunningham, D, Russell, C, Norman, A R, Kurzawinski, T, Harper, P, Harrison, P, Middleton, G, Daniels, F, Hickish, T, Prendeville, J, Ross, P J, Theis, B, Hull, R, Walker, M, Shankley, N, Kalindjian, B, Murray, G, Gillbanks, A, Black, J
Publicado 2006

Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

por Bennouna, J, Breton, J-L, Tourani, J-M, Ottensmeier, C, O'Brien, M, Kosmidis, P, Huat, T E, Pinel, M-C, Colin, C, Douillard, J-Y
Publicado 2006

A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

por Zelek, L, Yovine, A, Brain, E, Turpin, F, Taamma, A, Riofrio, M, Spielmann, M, Jimeno, J, Misset, J L
Publicado 2006

Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study

por Van den Eynden, G G, Van der Auwera, I, Van Laere, S J, Colpaert, C G, van Dam, P, Dirix, L Y, Vermeulen, P B, Van Marck, E A
Publicado 2006

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cance...

por Souglakos, J, Androulakis, N, Syrigos, K, Polyzos, A, Ziras, N, Athanasiadis, A, Kakolyris, S, Tsousis, S, Kouroussis, Ch, Vamvakas, L, Kalykaki, A, Samonis, G, Mavroudis, D, Georgoulias, V
Publicado 2006

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

por Vincenzi, B, Santini, D, Rabitti, C, Coppola, R, Beomonte Zobel, B, Trodella, L, Tonini, G
Publicado 2006

Diagnostic potential of near-infrared Raman spectroscopy in the stomach: differentiating dysplasia from normal tissue

por Teh, S K, Zheng, W, Ho, K Y, Teh, M, Yeoh, K G, Huang, Z
Publicado 2008

Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma

por Sersa, G, Jarm, T, Kotnik, T, Coer, A, Podkrajsek, M, Sentjurc, M, Miklavcic, D, Kadivec, M, Kranjc, S, Secerov, A, Cemazar, M
Publicado 2008

DNA replication licensing and cell cycle kinetics of normal and neoplastic breast

por Shetty, A, Loddo, M, Fanshawe, T, Prevost, A T, Sainsbury, R, Williams, G H, Stoeber, K
Publicado 2005

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

por Feliu, J, Castañón, C, Salud, A, Mel, J R, Escudero, P, Pelegrín, A, López-Gómez, L, Ruiz, M, González, E, Juárez, F, Lizón, J, Castro, J, González-Barón, M
Publicado 2005

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

por Fosså, S D, Paluchowska, B, Horwich, A, Kaiser, G, de Mulder, P H M, Koriakine, O, van Oosterom, A T, de Prijck, L, Collette, L, de Wit, R
Publicado 2005

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

por Hubeek, I, Stam, R W, Peters, G J, Broekhuizen, R, Meijerink, J P P, Wering, E R van, Gibson, B E S, Creutzig, U, Zwaan, C M, Cloos, J, Kuik, D J, Pieters, R, Kaspers, G J L
Publicado 2005

A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients wi...

por Takeda, Y, Tsuduki, E, Izumi, S, Hojo, M, Kamimura, M, Naka, G, Kobayashi, K, Kudo, K
Publicado 2005

Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia

por Olsen, J H, Hahnemann, J M D, Børresen-Dale, A-L, Tretli, S, Kleinerman, R, Sankila, R, Hammarström, L, Robsahm, T E, Kääriäinen, H, Bregård, A, Brøndum-Nielsen, K, Yuen, J, Tucker, M
Publicado 2005

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development

por Camidge, D R, Pemberton, M N, Growcott, J W, Johnstone, D, Laud, P J, Foster, J R, Randall, K J, Hughes, A M
Publicado 2005

Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk

por Lindmark, F, Zheng, S L, Wiklund, F, Bälter, K A, Sun, J, Chang, B, Hedelin, M, Clark, J, Johansson, J-E, Meyers, D A, Adami, H-O, Isaacs, W, Grönberg, H, Xu, J
Publicado 2005

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

por Conte, P F, Donati, S, Gennari, A, Guarneri, V, Orlandini, C, Rondini, M, Roncella, M, Marini, L, Collecchi, P, Viacava, P, Naccarato, A G, Degli Esposti, R, Bonardi, S, Bottini, A, Saracchini, S, Tumolo, S, Gullo, G, Santoro, A, Crino, L
Publicado 2005